Details for Patent: 8,034,370

Which drugs does patent 8,034,370 protect, and when does it expire?

Patent 8,034,370 protects OZURDEX and is included in one NDA.

This patent has ninety-one patent family members in twenty-six countries.

Summary for Patent: 8,034,370

Title:	Ocular implant made by a double extrusion process
Abstract:	The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
Inventor(s):	Shiah; Jane-Guo (Irvine, CA), Bhagat; Rahul (Irvine, CA), Blanda; Wendy M. (Tustin, CA), Nivaggioli; Thierry (Los Altos, CA), Peng; Lin (Palo Alto, CA), Chou; David (Palo Alto, CA), Weber; David A. (Danville, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	11/931,954
Patent Claim Types: see list of patent claims	Use; Device;

Drugs Protected by US Patent 8,034,370

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Allergan	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009		RX	Yes	Yes			Y

International Family Members for US Patent 8,034,370

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	051278
Austria	381319
Austria	555779
Australia	2004204744
Australia	2005290240
Australia	2010235967